{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:03:07Z","timestamp":1792648987800,"version":"4.5.0"},"reference-count":153,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s40263-015-0282-7","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T08:51:01Z","timestamp":1445331061000},"page":"819-832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":153,"title":["Anxiety in Patients with Schizophrenia: Epidemiology and Management"],"prefix":"10.1007","volume":"29","author":[{"given":"Henk","family":"Temmingh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,19]]},"reference":[{"issue":"4","key":"282_CR1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1600-0447.1987.tb02806.x","volume":"75","author":"RC Bland","year":"1987","unstructured":"Bland RC, Newman SC, Orn H. Schizophrenia: lifetime co-morbidity in a community sample. Acta Psychiatr Scand. 1987;75(4):383\u201391.","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"282_CR2","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1176\/ajp.143.12.1569","volume":"143","author":"JH Boyd","year":"1986","unstructured":"Boyd JH. Use of mental health services for the treatment of panic disorder. Am J Psychiatry. 1986;143(12):1569\u201374.","journal-title":"Am J Psychiatry"},{"issue":"2\u20133","key":"282_CR3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0920-9964(01)00373-5","volume":"58","author":"R Goodwin","year":"2002","unstructured":"Goodwin R, Lyons JS, McNally RJ. Panic attacks in schizophrenia. Schizophr Res. 2002;58(2\u20133):213\u201320.","journal-title":"Schizophr Res"},{"issue":"1","key":"282_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2013.07.030","volume":"210","author":"RJ Braga","year":"2013","unstructured":"Braga RJ, Reynolds GP, Siris SG. Anxiety comorbidity in schizophrenia. Psychiatry Res. 2013;210(1):1\u20137.","journal-title":"Psychiatry Res"},{"issue":"4","key":"282_CR5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/ajp.143.4.437","volume":"143","author":"WS Fenton","year":"1986","unstructured":"Fenton WS, McGlashan TH. The prognostic significance of obsessive-compulsive symptoms in schizophrenia. Am J Psychiatry. 1986;143(4):437\u201341.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"282_CR6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.comppsych.2005.08.007","volume":"47","author":"JE Wilk","year":"2006","unstructured":"Wilk JE, West JC, Narrow WE, Marcus S, Rubio-Stipec M, Rae DS, et al. Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis? Compr Psychiatry. 2006;47(4):258\u201364.","journal-title":"Compr Psychiatry"},{"key":"282_CR7","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013.","edition":"5"},{"issue":"4","key":"282_CR8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/schbul\/sbp148","volume":"37","author":"AM Achim","year":"2011","unstructured":"Achim AM, Maziade M, Raymond E, Olivier D, Merette C, Roy MA. How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association. Schizophr Bull. 2011;37(4):811\u201321.","journal-title":"Schizophr Bull"},{"issue":"2","key":"282_CR9","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/070674370605100206","volume":"51","author":"JM Somers","year":"2006","unstructured":"Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry Rev Can Psychiatr. 2006;51(2):100\u201313.","journal-title":"Can J Psychiatry Rev Can Psychiatr"},{"issue":"2","key":"282_CR10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/schbul\/sbn135","volume":"35","author":"PF Buckley","year":"2009","unstructured":"Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383\u2013402.","journal-title":"Schizophr Bull"},{"issue":"3","key":"282_CR11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1192\/bjp.bp.108.053124","volume":"195","author":"M Michail","year":"2009","unstructured":"Michail M, Birchwood M. Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia. Br J Psychiatry J Ment Sci. 2009;195(3):234\u201341.","journal-title":"Br J Psychiatry J Ment Sci"},{"key":"282_CR12","volume-title":"The ICD-10 classification of mental and behavioral disorders","author":"World Health Organization","year":"1992","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioral disorders. Geneva: Diagnostic Criteria for Research; 1992."},{"key":"282_CR13","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/P). New York: Biometrics Research, New York State Psychiatric Institute; 2002."},{"issue":"4","key":"282_CR14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.nmd.0000253782.47140.ac","volume":"195","author":"S Seedat","year":"2007","unstructured":"Seedat S, Fritelli V, Oosthuizen P, Emsley RA, Stein DJ. Measuring anxiety in patients with schizophrenia. J Nerv Ment Dis. 2007;195(4):320\u20134.","journal-title":"J Nerv Ment Dis"},{"issue":"11","key":"282_CR15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006\u201311.","journal-title":"Arch Gen Psychiatry"},{"key":"282_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3371\/CSRP.BOMA.091313","volume":"18","author":"P Bosanac","year":"2013","unstructured":"Bosanac P, Mancuso S, Castle D. Anxiety symptoms in psychotic disorders. Clin Schizophr Relat Psychoses. 2013;18:1\u201322.","journal-title":"Clin Schizophr Relat Psychoses"},{"issue":"11","key":"282_CR17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4088\/JCP.v60n1105","volume":"60","author":"RA Emsley","year":"1999","unstructured":"Emsley RA, Oosthuizen PP, Joubert AF, Roberts MC, Stein DJ. Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder. J Clin Psychiatry. 1999;60(11):747\u201351.","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"282_CR18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.psychres.2012.02.024","volume":"197","author":"S Faragian","year":"2012","unstructured":"Faragian S, Fuchs C, Pashinian A, Weizman R, Weizman A, Poyurovsky M. Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder. Psychiatry Res. 2012;197(1\u20132):19\u201322.","journal-title":"Psychiatry Res"},{"issue":"1\u20132","key":"282_CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.psychres.2007.06.010","volume":"159","author":"M Poyurovsky","year":"2008","unstructured":"Poyurovsky M, Faragian S, Shabeta A, Kosov A. Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder. Psychiatry Res. 2008;159(1\u20132):133\u20139.","journal-title":"Psychiatry Res"},{"issue":"1\u20133","key":"282_CR20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.schres.2015.03.007","volume":"164","author":"J Lim","year":"2015","unstructured":"Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RS, et al. Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis\u2014findings from the Longitudinal Youth at Risk Study (LYRIKS). Schizophr Res. 2015;164(1\u20133):8\u201314.","journal-title":"Schizophr Res"},{"key":"282_CR21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1192\/bjp.186.1.18","volume":"186","author":"EC Johnstone","year":"2005","unstructured":"Johnstone EC, Ebmeier KP, Miller P, Owens DG, Lawrie SM. Predicting schizophrenia: findings from the Edinburgh High-Risk Study. Br J Psychiatry J Ment Sci. 2005;186:18\u201325.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"1","key":"282_CR22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.1992.01820010037005","volume":"49","author":"AY Tien","year":"1992","unstructured":"Tien AY, Eaton WW. Psychopathologic precursors and sociodemographic risk factors for the schizophrenia syndrome. Arch Gen Psychiatry. 1992;49(1):37\u201346.","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"282_CR23","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/schbul\/sbu169","volume":"41","author":"M Cederlof","year":"2015","unstructured":"Cederlof M, Lichtenstein P, Larsson H, Boman M, Ruck C, Landen M, et al. Obsessive-compulsive disorder, psychosis, and bipolarity: a longitudinal cohort and multigenerational family study. Schizophr Bull. 2015;41(5):1076\u201383.","journal-title":"Schizophr Bull"},{"issue":"11","key":"282_CR24","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/jamapsychiatry.2014.1011","volume":"71","author":"SM Meier","year":"2014","unstructured":"Meier SM, Petersen L, Pedersen MG, Arendt MC, Nielsen PR, Mattheisen M, et al. Obsessive-compulsive disorder as a risk factor for schizophrenia: a nationwide study. JAMA Psychiatry. 2014;71(11):1215\u201321.","journal-title":"JAMA Psychiatry"},{"key":"282_CR25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1192\/bjp.186.5.386","volume":"186","author":"DG Owens","year":"2005","unstructured":"Owens DG, Miller P, Lawrie SM, Johnstone EC. Pathogenesis of schizophrenia: a psychopathological perspective. Br J Psychiatry J Ment Sci. 2005;186:386\u201393.","journal-title":"Br J Psychiatry J Ment Sci"},{"issue":"6","key":"282_CR26","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/NMD.0000000000000311","volume":"203","author":"AB Veras","year":"2015","unstructured":"Veras AB, Souza TG, Ricci TG, de Souza CP, Moryiama MC, Nardi AE, et al. Paranoid delusional disorder follows social anxiety disorder in a long-term case series: evolutionary perspective. J Nerv Ment Dis. 2015;203(6):477\u20139.","journal-title":"J Nerv Ment Dis"},{"issue":"1","key":"282_CR27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/schbul\/sbs136","volume":"40","author":"P Fusar-Poli","year":"2014","unstructured":"Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK. Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull. 2014;40(1):120\u201331.","journal-title":"Schizophr Bull"},{"issue":"3","key":"282_CR28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/jts.20114","volume":"19","author":"PS Calhoun","year":"2006","unstructured":"Calhoun PS, Bosworth HB, Stechuchak KA, Strauss J, Butterfield MI. The impact of posttraumatic stress disorder on quality of life and health service utilization among veterans who have schizophrenia. J Trauma Stress. 2006;19(3):393\u20137.","journal-title":"J Trauma Stress"},{"issue":"1","key":"282_CR29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.schbul.a007067","volume":"30","author":"KT Mueser","year":"2004","unstructured":"Mueser KT, Salyers MP, Rosenberg SD, Goodman LA, Essock SM, Osher FC, et al. Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates. Schizophr Bull. 2004;30(1):45\u201357.","journal-title":"Schizophr Bull"},{"issue":"11","key":"282_CR30","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1176\/appi.ps.201300316","volume":"65","author":"DG Birgenheir","year":"2014","unstructured":"Birgenheir DG, Ganoczy D, Bowersox NW. Service utilization among veterans with schizophrenia and a comorbid anxiety disorder. Psychiatr Serv. 2014;65(11):1354\u20139.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"282_CR31","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.comppsych.2004.07.009","volume":"45","author":"RJ Braga","year":"2004","unstructured":"Braga RJ, Petrides G, Figueira I. Anxiety disorders in schizophrenia. Compr Psychiatry. 2004;45(6):460\u20138.","journal-title":"Compr Psychiatry"},{"issue":"2\u20133","key":"282_CR32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0920-9964(99)00151-6","volume":"51","author":"JD Huppert","year":"2001","unstructured":"Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE. Quality of life in schizophrenia: contributions of anxiety and depression. Schizophr Res. 2001;51(2\u20133):171\u201380.","journal-title":"Schizophr Res"},{"issue":"1","key":"282_CR33","first-page":"40","volume":"52","author":"KM Lowengrub","year":"2015","unstructured":"Lowengrub KM, Stryjer R, Birger M, Iancu I. Social anxiety disorder comorbid with schizophrenia: the importance of screening for this under recognized and under treated condition. Isr J Psychiatry Relat Sci. 2015;52(1):40\u20135.","journal-title":"Isr J Psychiatry Relat Sci"},{"issue":"7","key":"282_CR34","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.pnpbp.2010.07.014","volume":"34","author":"H Ulas","year":"2010","unstructured":"Ulas H, Polat S, Akdede BB, Alptekin K. Impact of panic attacks on quality of life among patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1300\u20135.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"282_CR35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1751-7893.2012.00377.x","volume":"7","author":"L Haan de","year":"2013","unstructured":"de Haan L, Sterk B, van der Valk R. Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life. Early Interv Psychiatry. 2013;7(3):285\u201390.","journal-title":"Early Interv Psychiatry"},{"issue":"1","key":"282_CR36","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.psychres.2015.01.021","volume":"226","author":"SW Kim","year":"2015","unstructured":"Kim SW, Jeong BO, Kim JM, Shin IS, Hwang MY, Paul Amminger G, et al. Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness. Psychiatry Res. 2015;226(1):368\u201375.","journal-title":"Psychiatry Res"},{"key":"282_CR37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.comppsych.2014.09.015","volume":"56","author":"S Devi","year":"2015","unstructured":"Devi S, Rao NP, Badamath S, Chandrashekhar CR, Reddy YCJ. Prevalence and clinical correlates of obsessive-compulsive disorder in schizophrenia. Compr Psychiatry. 2015;56:141\u20138.","journal-title":"Compr Psychiatry"},{"issue":"1","key":"282_CR38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/schbul\/sbr077","volume":"39","author":"L Haan de","year":"2013","unstructured":"de Haan L, Sterk B, Wouters L, Linszen DH. The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders. Schizophr Bull. 2013;39(1):151\u201360.","journal-title":"Schizophr Bull"},{"key":"282_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-244X-10-75","volume":"10","author":"AW Nyhuis","year":"2010","unstructured":"Nyhuis AW, Faries DE, Ascher-Svanum H, Stauffer VL, Kinon BJ. Predictors of switching antipsychotic medications in the treatment of schizophrenia. BMC Psychiatry. 2010;10:75.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"282_CR40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/da.10083","volume":"17","author":"P Tibbo","year":"2003","unstructured":"Tibbo P, Swainson J, Chue P, LeMelledo JM. Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia. Depress Anxiety. 2003;17(2):65\u201372.","journal-title":"Depress Anxiety"},{"issue":"2","key":"282_CR41","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2975\/32.2.2008.132.134","volume":"32","author":"PH Lysaker","year":"2008","unstructured":"Lysaker PH, Ringer JM, Davis LW. Associations of social anxiety and self-esteem across six months for persons living with schizophrenia spectrum disorders. Psychiatr Rehabil J. 2008;32(2):132\u20134.","journal-title":"Psychiatr Rehabil J"},{"key":"282_CR42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-244X-14-166","volume":"14","author":"K Naidu","year":"2014","unstructured":"Naidu K, van Staden WC, van der Linde M. Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia. BMC Psychiatry. 2014;14:166.","journal-title":"BMC Psychiatry"},{"issue":"8","key":"282_CR43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/NMD.0000000000000169","volume":"202","author":"M Dombrowski","year":"2014","unstructured":"Dombrowski M, McCleery A, Gregory SW Jr, Docherty NM. Stress reactivity of emotional and verbal speech content in schizophrenia. J Nerv Ment Dis. 2014;202(8):608\u201312.","journal-title":"J Nerv Ment Dis."},{"issue":"2","key":"282_CR44","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00005053-200002000-00003","volume":"188","author":"PH Lysaker","year":"2000","unstructured":"Lysaker PH, Marks KA, Picone JB, Rollins AL, Fastenau PS, Bond GR. Obsessive and compulsive symptoms in schizophrenia: clinical and neurocognitive correlates. J Nerv Ment Dis. 2000;188(2):78\u201383.","journal-title":"J Nerv Ment Dis."},{"issue":"11","key":"282_CR45","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.4088\/JCP.v64n1104","volume":"64","author":"M Poyurovsky","year":"2003","unstructured":"Poyurovsky M, Kriss V, Weisman G, Faragian S, Kurs R, Schneidman M, et al. Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia. J Clin Psychiatry. 2003;64(11):1300\u20137.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"282_CR46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4088\/JCP.07r03618","volume":"70","author":"R Cunill","year":"2009","unstructured":"Cunill R, Castells X, Simeon D. Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis. J Clin Psychiatry. 2009;70(1):70\u201382.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"282_CR47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.psychres.2015.02.017","volume":"227","author":"S Sutliff","year":"2015","unstructured":"Sutliff S, Roy MA, Achim AM. Social anxiety disorder in recent onset schizophrenia spectrum disorders: the relation with symptomatology, anxiety, and social rank. Psychiatry Res. 2015;227(1):39\u201345.","journal-title":"Psychiatry Res"},{"issue":"1","key":"282_CR48","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1176\/jnp.12.1.91","volume":"12","author":"MY Hwang","year":"2000","unstructured":"Hwang MY, Morgan JE, Losconzcy MF. Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study. J Neuropsychiatry Clin Neurosci. 2000;12(1):91\u20134.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"6","key":"282_CR49","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1027\/0227-5910\/a000211","volume":"34","author":"N Jovanovic","year":"2013","unstructured":"Jovanovic N, Podlesek A, Medved V, Grubisin J, Mihaljevic-Peles A, Goran T, et al. Association between psychopathology and suicidal behavior in schizophrenia. A cross-sectional study of 509 participants. Crisis. 2013;34(6):374\u201381.","journal-title":"Crisis"},{"issue":"1","key":"282_CR50","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.psychres.2013.05.013","volume":"210","author":"J Tsai","year":"2013","unstructured":"Tsai J, Rosenheck RA. Psychiatric comorbidity among adults with schizophrenia: a latent class analysis. Psychiatry Res. 2013;210(1):16\u201320.","journal-title":"Psychiatry Res"},{"issue":"9","key":"282_CR51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/NMD.0b013e318142ce67","volume":"195","author":"M Poyurovsky","year":"2007","unstructured":"Poyurovsky M, Faragian S, Kleinman-Balush V, Pashinian A, Kurs R, Fuchs C. Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder. J Nerv Ment Dis. 2007;195(9):765\u20138.","journal-title":"J Nerv Ment Dis"},{"issue":"6","key":"282_CR52","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1017\/S0033291714002372","volume":"45","author":"M Nierop van","year":"2015","unstructured":"van Nierop M, Viechtbauer W, Gunther N, van Zelst C, de Graaf R, Ten Have M, et al. Childhood trauma is associated with a specific admixture of affective, anxiety, and psychosis symptoms cutting across traditional diagnostic boundaries. Psychol Med. 2015;45(6):1277\u201388.","journal-title":"Psychol Med"},{"issue":"1","key":"282_CR53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.psychres.2013.05.029","volume":"210","author":"R Cunill","year":"2013","unstructured":"Cunill R, Huerta-Ramos E, Castells X. The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis. Psychiatry Res. 2013;210(1):21\u20138.","journal-title":"Psychiatry Res"},{"issue":"6","key":"282_CR54","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/schbul\/sbs123","volume":"39","author":"F Schirmbeck","year":"2013","unstructured":"Schirmbeck F, Rausch F, Englisch S, Eifler S, Esslinger C, Meyer-Lindenberg A, et al. Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study. Schizophr Bull. 2013;39(6):1261\u201371.","journal-title":"Schizophr Bull"},{"key":"282_CR55","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fpsyg.2013.00136","volume":"4","author":"I Halasz","year":"2013","unstructured":"Halasz I, Levy-Gigi E, Kelemen O, Benedek G, Keri S. Neuropsychological functions and visual contrast sensitivity in schizophrenia: the potential impact of comorbid posttraumatic stress disorder (PTSD). Front Psychol. 2013;4:136.","journal-title":"Front Psychol"},{"key":"282_CR56","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1146\/annurev.clinpsy.2.022305.095213","volume":"2","author":"RF Krueger","year":"2006","unstructured":"Krueger RF, Markon KE. Reinterpreting comorbidity: a model-based approach to understanding and classifying psychopathology. Annu Rev Clin Psychol. 2006;2:111\u201333.","journal-title":"Annu Rev Clin Psychol"},{"issue":"1","key":"282_CR57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2045-5380-2-13","volume":"2","author":"S Ofrat","year":"2012","unstructured":"Ofrat S, Krueger RF. How research on the meta-structure of psychopathology aids in understanding biological correlates of mood and anxiety disorders. Biol Mood Anxiety Disord. 2012;2(1):13.","journal-title":"Biol Mood Anxiety Disord"},{"issue":"3","key":"282_CR58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00127-014-1004-z","volume":"50","author":"N Carragher","year":"2015","unstructured":"Carragher N, Krueger RF, Eaton NR, Slade T. Disorders without borders: current and future directions in the meta-structure of mental disorders. Soc Psychiatry Psychiatr Epidemiol. 2015;50(3):339\u201350.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"4","key":"282_CR59","first-page":"219","volume":"10","author":"F Seedat","year":"2007","unstructured":"Seedat F, Roos JL, Pretorius HW, Karayiorgou M, Nel B. Prevalence and clinical characteristics of obsessive-compulsive disorder and obsessive compulsive symptoms in Afrikaner schizophrenia and schizoaffective disorder patients. Afr J Psychiatry (Johannesbg). 2007;10(4):219\u201324.","journal-title":"Afr J Psychiatry (Johannesbg)."},{"issue":"9","key":"282_CR60","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1177\/0004867413491156","volume":"47","author":"N Dekker","year":"2013","unstructured":"Dekker N, Swets M. Substance use in a large sample of patients with schizophrenia or related disorders and co-morbid obsessive-compulsive symptoms. Aust N Z J Psychiatry. 2013;47(9):868\u201374.","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"282_CR61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0920-9964(02)00292-X","volume":"61","author":"RD Goodwin","year":"2003","unstructured":"Goodwin RD, Amador XF, Malaspina D, Yale SA, Goetz RR, Gorman JM. Anxiety and substance use comorbidity among inpatients with schizophrenia. Schizophr Res. 2003;61(1):89\u201395.","journal-title":"Schizophr Res"},{"issue":"2","key":"282_CR62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/oxfordjournals.schbul.a006933","volume":"28","author":"G Scheller-Gilkey","year":"2002","unstructured":"Scheller-Gilkey G, Thomas SM, Woolwine BJ, Miller AH. Increased early life stress and depressive symptoms in patients with comorbid substance abuse and schizophrenia. Schizophr Bull. 2002;28(2):223\u201331.","journal-title":"Schizophr Bull."},{"issue":"5","key":"282_CR63","first-page":"283","volume":"77","author":"A Aleman","year":"2005","unstructured":"Aleman A, Kahn RS. Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia? Prog Neurobiol. 2005;77(5):283\u201398.","journal-title":"Prog Neurobiol"},{"key":"282_CR64","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-clinpsy-050212-185538","volume":"9","author":"AM Kring","year":"2013","unstructured":"Kring AM, Elis O. Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol. 2013;9:409\u201333.","journal-title":"Annu Rev Clin Psychol"},{"issue":"12","key":"282_CR65","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1016\/j.neuropsychologia.2010.08.021","volume":"48","author":"P Roux","year":"2010","unstructured":"Roux P, Christophe A, Passerieux C. The emotional paradox: dissociation between explicit and implicit processing of emotional prosody in schizophrenia. Neuropsychologia. 2010;48(12):3642\u20139.","journal-title":"Neuropsychologia"},{"issue":"5","key":"282_CR66","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/schbul\/sbn190","volume":"36","author":"H Li","year":"2010","unstructured":"Li H, Chan RC, McAlonan GM, Gong QY. Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data. Schizophr Bull. 2010;36(5):1029\u201339.","journal-title":"Schizophr Bull"},{"issue":"10","key":"282_CR67","doi-asserted-by":"crossref","first-page":"e25322","DOI":"10.1371\/journal.pone.0025322","volume":"6","author":"G Sugranyes","year":"2011","unstructured":"Sugranyes G, Kyriakopoulos M, Corrigall R, Taylor E, Frangou S. Autism spectrum disorders and schizophrenia: meta-analysis of the neural correlates of social cognition. PLoS One. 2011;6(10):e25322.","journal-title":"PLoS One"},{"issue":"3","key":"282_CR68","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.psychres.2006.03.010","volume":"150","author":"M Wout van \u2018t","year":"2007","unstructured":"van \u2018t Wout M, Aleman A, Kessels RP, Cahn W, de Haan EH, Kahn RS. Exploring the nature of facial affect processing deficits in schizophrenia. Psychiatry Res. 2007;150(3):227\u201335.","journal-title":"Psychiatry Res"},{"issue":"2","key":"282_CR69","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1037\/0021-843X.105.2.249","volume":"105","author":"AM Kring","year":"1996","unstructured":"Kring AM, Neale JM. Do schizophrenic patients show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion? J Abnorm Psychol. 1996;105(2):249\u201357.","journal-title":"J Abnorm Psychol"},{"issue":"3","key":"282_CR70","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1176\/appi.ajp.161.3.480","volume":"161","author":"LM Williams","year":"2004","unstructured":"Williams LM, Das P, Harris AW, Liddell BB, Brammer MJ, Olivieri G, et al. Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia. Am J Psychiatry. 2004;161(3):480\u20139.","journal-title":"Am J Psychiatry"},{"issue":"16","key":"282_CR71","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1097\/00001756-200211150-00029","volume":"13","author":"H Yamasue","year":"2002","unstructured":"Yamasue H, Fukui T, Fukuda R, Yamada H, Yamasaki S, Kuroki N, et al. 1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia. NeuroReport. 2002;13(16):2133\u20137.","journal-title":"NeuroReport"},{"issue":"8","key":"282_CR72","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archpsyc.57.8.769","volume":"57","author":"RE Gur","year":"2000","unstructured":"Gur RE, Turetsky BI, Cowell PE, Finkelman C, Maany V, Grossman RI, et al. Temporolimbic volume reductions in schizophrenia. Arch Gen Psychiatry. 2000;57(8):769\u201375.","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"282_CR73","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/YPG.0b013e328360c866","volume":"23","author":"MM Sun","year":"2013","unstructured":"Sun MM, Yang LM, Wang Y, Feng X, Cui KY, Liu LF, et al. BDNF Val66Met polymorphism and anxiety\/depression symptoms in schizophrenia in a Chinese Han population. Psychiatr Genet. 2013;23(3):124\u20139.","journal-title":"Psychiatr Genet"},{"issue":"1","key":"282_CR74","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1385\/NI:4:1:51","volume":"4","author":"K Xu","year":"2006","unstructured":"Xu K, Ernst M, Goldman D. Imaging genomics applied to anxiety, stress response, and resiliency. Neuroinformatics. 2006;4(1):51\u201364.","journal-title":"Neuroinformatics"},{"issue":"44","key":"282_CR75","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.pnpbp.2013.04.003","volume":"1","author":"W Li","year":"2013","unstructured":"Li W, Yang Y, Lin J, Wang S, Zhao J, Yang G, et al. Association of serotonin transporter gene (SLC6A4) polymorphisms with schizophrenia susceptibility and symptoms in a Chinese-Han population. Prog Neuropsychopharmacol Biol Psychiatry. 2013;1(44):290\u20135.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"282_CR76","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","volume":"27","author":"P Celada","year":"2013","unstructured":"Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs. 2013;27(9):703\u201316.","journal-title":"CNS Drugs."},{"issue":"4","key":"282_CR77","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/13543784.2014.987339","volume":"24","author":"RP Garay","year":"2015","unstructured":"Garay RP, Samalin L, Hameg A, Llorca PM. Investigational drugs for anxiety in patients with schizophrenia. Expert Opin Investig Drugs. 2015;24(4):507\u201317.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"282_CR78","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/00004714-200108000-00015","volume":"21","author":"P Sirota","year":"2001","unstructured":"Sirota P, Epstein B, Benatov R, Sousnostzky M, Kindler S. An open study of buspirone augmentation of neuroleptics in patients with schizophrenia. J Clin Psychopharmacol. 2001;21(4):454\u20135.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"282_CR79","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/JCP.0b013e3181e5c095","volume":"30","author":"S Englisch","year":"2010","unstructured":"Englisch S, Esser A, Enning F, Hohmann S, Schanz H, Zink M. Augmentation with pregabalin in schizophrenia. J Clin Psychopharmacol. 2010;30(4):437\u201340.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"282_CR80","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/WNF.0b013e318220d8c6","volume":"34","author":"C Miodownik","year":"2011","unstructured":"Miodownik C, Maayan R, Ratner Y, Lerner V, Pintov L, Mar M, et al. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to l-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Clin Neuropharmacol. 2011;34(4):155\u201360.","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"282_CR81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4088\/JCP.09m05324gre","volume":"72","author":"MS Ritsner","year":"2011","unstructured":"Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, et al. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. J Clin Psychiatry. 2011;72(1):34\u201342.","journal-title":"J Clin Psychiatry."},{"key":"282_CR82","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1038\/tp.2013.34","volume":"3","author":"MJ Bakermans-Kranenburg","year":"2013","unstructured":"Bakermans-Kranenburg MJ, van I Jzendoorn MH. Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry. 2013;3:e258.","journal-title":"Transl Psychiatry."},{"issue":"8","key":"282_CR83","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/npp.2015.41","volume":"40","author":"NY Shin","year":"2015","unstructured":"Shin NY, Park HY, Jung WH, Park JW, Yun JY, Jang JH, et al. Effects of oxytocin on neural response to facial expressions in patients with schizophrenia. Neuropsychopharmacology. 2015;40(8):1919\u201327.","journal-title":"Neuropsychopharmacology."},{"issue":"5","key":"282_CR84","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/ph5050529","volume":"5","author":"S Zhornitsky","year":"2012","unstructured":"Zhornitsky S, Potvin S. Cannabidiol in humans-the quest for therapeutic targets. Pharmaceuticals (Basel). 2012;5(5):529\u201352.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"282_CR85","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2466\/pr0.2001.89.1.95","volume":"89","author":"A Cedro","year":"2001","unstructured":"Cedro A, Kokoszka A, Popiel A, Narkiewicz-Jodko W. Alexithymia in schizophrenia: an exploratory study. Psychol Rep. 2001;89(1):95\u20138.","journal-title":"Psychol Rep"},{"issue":"1\u20132","key":"282_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2014.04.020","volume":"218","author":"R Fogley","year":"2014","unstructured":"Fogley R, Warman D, Lysaker PH. Alexithymia in schizophrenia: associations with neurocognition and emotional distress. Psychiatry Res. 2014;218(1\u20132):1\u20136.","journal-title":"Psychiatry Res"},{"issue":"1","key":"282_CR87","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.comppsych.2006.07.003","volume":"48","author":"M Wout van \u2018t","year":"2007","unstructured":"van \u2018t Wout M, Aleman A, Bermond B, Kahn RS. No words for feelings: alexithymia in schizophrenia patients and first-degree relatives. Compr Psychiatry. 2007;48(1):27\u201333.","journal-title":"Compr Psychiatry."},{"key":"282_CR88","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000414022","volume":"22","author":"MR Liebowitz","year":"1987","unstructured":"Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry. 1987;22:141\u201373.","journal-title":"Mod Probl Pharmacopsychiatry"},{"issue":"11","key":"282_CR89","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1176\/ajp.154.11.1571","volume":"154","author":"MK Shear","year":"1997","unstructured":"Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997;154(11):1571\u20135.","journal-title":"Am J Psychiatry"},{"issue":"12","key":"282_CR90","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1017\/S1092852900010488","volume":"10","author":"DJ Stein","year":"2005","unstructured":"Stein DJ. Generalized anxiety disorder: rethinking diagnosis and rating. CNS Spectr. 2005;10(12):930\u20134.","journal-title":"CNS Spectr"},{"issue":"2","key":"282_CR91","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1017\/S1352465812000422","volume":"41","author":"L Stopa","year":"2013","unstructured":"Stopa L, Denton R, Wingfield M, Taylor KN. The fear of others: a qualitative analysis of interpersonal threat in social phobia and paranoia. Behav Cogn Psychother. 2013;41(2):188\u2013209.","journal-title":"Behav Cogn Psychother."},{"issue":"4","key":"282_CR92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jpsychires.2004.09.004","volume":"39","author":"M Poyurovsky","year":"2005","unstructured":"Poyurovsky M, Koran LM. Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications. J Psychiatr Res. 2005;39(4):399\u2013408.","journal-title":"J Psychiatr Res"},{"issue":"14","key":"282_CR93","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00023210-200418140-00004","volume":"18","author":"M Poyurovsky","year":"2004","unstructured":"Poyurovsky M, Weizman A, Weizman R. Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment. CNS Drugs. 2004;18(14):989\u20131010.","journal-title":"CNS Drugs."},{"issue":"5","key":"282_CR94","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.comppsych.2011.08.009","volume":"53","author":"M Poyurovsky","year":"2012","unstructured":"Poyurovsky M, Zohar J, Glick I, Koran LM, Weizman R, Tandon R, et al. Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications. Compr Psychiatry. 2012;53(5):480\u20133.","journal-title":"Compr Psychiatry"},{"issue":"5","key":"282_CR95","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.comppsych.2014.03.016","volume":"55","author":"A Frias","year":"2014","unstructured":"Frias A, Palma C, Farriols N, Salvador A, Bonet J, Bernaldez I. Psychopathology and quality of life among patients with comorbidity between schizophrenia spectrum disorder and obsessive-compulsive disorder: no evidence for a \u201cschizo-obsessive\u201d subtype. Compr Psychiatry. 2014;55(5):1165\u201373.","journal-title":"Compr Psychiatry"},{"key":"282_CR96","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.","edition":"4"},{"issue":"11","key":"282_CR97","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1097\/NMD.0000000000000033","volume":"201","author":"S Bendall","year":"2013","unstructured":"Bendall S, Hulbert CA, Alvarez-Jimenez M, Allott K, McGorry PD, Jackson HJ. Testing a model of the relationship between childhood sexual abuse and psychosis in a first-episode psychosis group: the role of hallucinations and delusions, posttraumatic intrusions, and selective attention. J Nerv Ment Dis. 2013;201(11):941\u20137.","journal-title":"J Nerv Ment Dis."},{"issue":"5","key":"282_CR98","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1017\/S0033291711001826","volume":"42","author":"F Varese","year":"2012","unstructured":"Varese F, Barkus E, Bentall RP. Dissociation mediates the relationship between childhood trauma and hallucination-proneness. Psychol Med. 2012;42(5):1025\u201336.","journal-title":"Psychol Med"},{"key":"282_CR99","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TR Barnes","year":"1989","unstructured":"Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672\u20136.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"282_CR100","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50\u20135.","journal-title":"Br J Med Psychol"},{"issue":"1","key":"282_CR101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/jts.2490080106","volume":"8","author":"DD Blake","year":"1995","unstructured":"Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995;8(1):75\u201390.","journal-title":"J Trauma Stress"},{"key":"282_CR102","unstructured":"PROMIS-Emotional Distress-Anxiety-Short-form. Level 2-anxiety-adult. 2008\u20132012 ed. PROMIS Health Organization and PROMIS Cooperative Group; 2008\u20132012."},{"key":"282_CR103","unstructured":"American Psychiatric Association. Clinician-rated dimensions of psychosis symptom severity scale. 2013 [cited 2015 28 May 2015]. http:\/\/www.psychiatry.org\/dsm5 ."},{"issue":"2","key":"282_CR104","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376.","journal-title":"Schizophr Bull."},{"key":"282_CR105","first-page":"534","volume-title":"ECDEU assessment manual for psychopharmacology-revised (DHHS Publ No ADM 91-338)","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology-revised (DHHS Publ No ADM 91-338). Rockville: US Department of Health and Human Services; 1976. p. 534\u20137."},{"issue":"2","key":"282_CR106","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00406-013-0416-1","volume":"264","author":"PM Llorca","year":"2014","unstructured":"Llorca PM, Lancon C, Blanc O, de Chazeron I, Samalin L, Caci H, et al. A composite scale applied to evaluate anxiety in schizophrenic patients (SAES). Eur Arch Psychiatry Clin Neurosci. 2014;264(2):171\u20138.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"Pt 2","key":"282_CR107","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1348\/147608305X91538","volume":"79","author":"F Naeem","year":"2006","unstructured":"Naeem F, Kingdon D, Turkington D. Cognitive behaviour therapy for schizophrenia: relationship between anxiety symptoms and therapy. Psychol Psychother. 2006;79(Pt 2):153\u201364.","journal-title":"Psychol Psychother."},{"issue":"1","key":"282_CR108","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/schbul\/sbp130","volume":"36","author":"J Kreyenbuhl","year":"2010","unstructured":"Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94\u2013103.","journal-title":"Schizophr Bull"},{"issue":"9","key":"282_CR109","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4088\/JCP.v67n0902","volume":"67","author":"K Gao","year":"2006","unstructured":"Gao K, Muzina D, Gajwani P, Calabrese JR. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry. 2006;67(9):1327\u201340.","journal-title":"J Clin Psychiatry."},{"issue":"4","key":"282_CR110","first-page":"170","volume":"47","author":"J Mendels","year":"1986","unstructured":"Mendels J, Krajewski TF, Huffer V, Taylor RJ, Secunda S, Schless A, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry. 1986;47(4):170\u20134.","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"282_CR111","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004714-199602000-00007","volume":"16","author":"O Blin","year":"1996","unstructured":"Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16(1):38\u201344.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"282_CR112","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.euroneuro.2010.12.007","volume":"21","author":"NC Vulink","year":"2011","unstructured":"Vulink NC, Figee M, Denys D. Review of atypical antipsychotics in anxiety. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2011;21(6):429\u201349.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"issue":"9","key":"282_CR113","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1185\/030079904125004510","volume":"20","author":"PF Buckley","year":"2004","unstructured":"Buckley PF. Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials. Curr Med Res Opin. 2004;20(9):1357\u201363.","journal-title":"Curr Med Res Opin"},{"key":"282_CR114","doi-asserted-by":"crossref","unstructured":"Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev. 2010;12:CD008120.","DOI":"10.1002\/14651858.CD008120.pub2"},{"issue":"1","key":"282_CR115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/da.20017","volume":"20","author":"S Kasper","year":"2004","unstructured":"Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety. 2004;20(1):44\u20137.","journal-title":"Depress Anxiety"},{"issue":"4","key":"282_CR116","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e3283430a0e","volume":"26","author":"S Zhornitsky","year":"2011","unstructured":"Zhornitsky S, Potvin S, Moteshafi H, Dubreucq S, Rompre PP, Stip E. Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials. Int Clin Psychopharmacol. 2011;26(4):183\u201392.","journal-title":"Int Clin Psychopharmacol"},{"key":"282_CR117","doi-asserted-by":"crossref","unstructured":"Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11:CD006625.","DOI":"10.1002\/14651858.CD006625.pub3"},{"issue":"1","key":"282_CR118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/YIC.0000000000000053","volume":"30","author":"S Kasper","year":"2015","unstructured":"Kasper S, Montagnani G, Trespi G, Di Fiorino M. Treatment of depressive symptoms in patients with schizophrenia: a randomized, open-label, parallel-group, flexible-dose subgroup analysis of patients treated with extended-release quetiapine fumarate or risperidone. Int Clin Psychopharmacol. 2015;30(1):14\u201322.","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"282_CR119","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71\u201393.","journal-title":"Schizophr Bull"},{"issue":"12","key":"282_CR120","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.4088\/JCP.v69n1202","volume":"69","author":"ID Glick","year":"2008","unstructured":"Glick ID, Poyurovsky M, Ivanova O, Koran LM. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. J Clin Psychiatry. 2008;69(12):1856\u20139.","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"282_CR121","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","volume":"14","author":"D Veale","year":"2014","unstructured":"Veale D, Miles S, Smallcombe N, Ghezai H, Goldacre B, Hodsoll J. Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis. BMC Psychiatry. 2014;14(1):317.","journal-title":"BMC Psychiatry"},{"issue":"18","key":"282_CR122","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00213-014-3516-3","volume":"231","author":"D Ducasse","year":"2014","unstructured":"Ducasse D, Boyer L, Michel P, Loundou A, Macgregor A, Micoulaud-Franchi JA, et al. D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. Psychopharmacology. 2014;231(18):3765\u201370.","journal-title":"Psychopharmacology"},{"issue":"3","key":"282_CR123","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/JCP.0b013e3181a48e12","volume":"29","author":"RG Stern","year":"2009","unstructured":"Stern RG, Petti TA, Bopp K, Tobia A. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study. J Clin Psychopharmacol. 2009;29(3):206\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"35 Suppl","key":"282_CR124","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0920-9964(98)00164-9","volume":"1","author":"GD Tollefson","year":"1999","unstructured":"Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy? Schizophr Res. 1999;1(35 Suppl):S13\u201321.","journal-title":"Schizophr Res"},{"issue":"3","key":"282_CR125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004714-199506000-00009","volume":"15","author":"I Berman","year":"1995","unstructured":"Berman I, Sapers BL, Chang HH, Losonczy MF, Schmildler J, Green AI. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. J Clin Psychopharmacol. 1995;15(3):206\u201310.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"282_CR126","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00004714-200008000-00004","volume":"20","author":"I Reznik","year":"2000","unstructured":"Reznik I, Sirota P. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. J Clin Psychopharmacol. 2000;20(4):410\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"282_CR127","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0269881103017001713","volume":"17","author":"C Mulholland","year":"2003","unstructured":"Mulholland C, Lynch G, King DJ, Cooper SJ. A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia. J Psychopharmacol. 2003;17(1):107\u201312.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"282_CR128","doi-asserted-by":"crossref","first-page":"819","DOI":"10.4088\/JCP.v60n1203","volume":"60","author":"S Pallanti","year":"1999","unstructured":"Pallanti S, Quercioli L, Rossi A, Pazzagli A. The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation. J Clin Psychiatry. 1999;60(12):819\u201323.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"282_CR129","first-page":"291","volume":"42","author":"V Agarwal","year":"2000","unstructured":"Agarwal V, Agarwal KM. Treatment of obsessive compulsive symptoms in schizophrenia with fluoxetine. Indian J Psychiatry. 2000;42(3):291\u20134.","journal-title":"Indian J Psychiatry"},{"issue":"2","key":"282_CR130","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/YIC.0b013e32835bd24e","volume":"28","author":"R Stryjer","year":"2013","unstructured":"Stryjer R, Dambinsky Y, Timinsky I, Green T, Kotler M, Weizman A, et al. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study. Int Clin Psychopharmacol. 2013;28(2):96\u20138.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"282_CR131","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/00002826-200005000-00005","volume":"23","author":"I Reznik","year":"2000","unstructured":"Reznik I, Sirota P. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms. Clin Neuropharmacol. 2000;23(3):157\u201360.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"282_CR132","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00004850-199903000-00006","volume":"14","author":"M Poyurovsky","year":"1999","unstructured":"Poyurovsky M, Isakov V, Hromnikov S, Modai I, Rauchberger B, Schneidman M, et al. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol. 1999;14(2):95\u2013100.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"282_CR133","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/15622975.2015.1009163","volume":"16","author":"A Hasan","year":"2015","unstructured":"Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 3: update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry. 2015;16(3):142\u201370.","journal-title":"World J Biol Psychiatry Off J World Fed Soc Biol Psychiatry"},{"issue":"2","key":"282_CR134","first-page":"343","volume":"17","author":"T Kishi","year":"2014","unstructured":"Kishi T, Iwata N. Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol. 2014;17(2):343\u201354.","journal-title":"Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol"},{"key":"282_CR135","doi-asserted-by":"crossref","unstructured":"Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev. 2006;3:CD005581.","DOI":"10.1002\/14651858.CD005581"},{"issue":"2","key":"282_CR136","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","volume":"16","author":"B Bandelow","year":"2012","unstructured":"Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012;16(2):77\u201384.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"7","key":"282_CR137","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0149-2918(08)80047-1","volume":"30","author":"E Spina","year":"2008","unstructured":"Spina E, Santoro V, D\u2019Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206\u201327.","journal-title":"Clin Ther"},{"key":"282_CR138","first-page":"701","volume":"11","author":"YM Mao","year":"2015","unstructured":"Mao YM, Zhang MD. Augmentation with antidepressants in schizophrenia treatment: benefit or risk. Neuropsychiatr Dis Treat. 2015;11:701\u201313.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"282_CR139","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.4088\/JCP.13r08672","volume":"75","author":"SR Beach","year":"2014","unstructured":"Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441\u20139.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"282_CR140","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1177\/1060028013501994","volume":"47","author":"KA Funk","year":"2013","unstructured":"Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330\u201341.","journal-title":"Ann Pharmacother"},{"issue":"6","key":"282_CR141","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jama.288.6.701","volume":"288","author":"AH Glassman","year":"2002","unstructured":"Glassman AH, O\u2019Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288(6):701\u20139.","journal-title":"JAMA"},{"issue":"2","key":"282_CR142","doi-asserted-by":"crossref","first-page":"127","DOI":"10.31887\/DCNS.2015.17.2\/nmavrides","volume":"17","author":"N Mavrides","year":"2015","unstructured":"Mavrides N, Nemeroff CB. Treatment of affective disorders in cardiac disease. Dialogues Clin Neurosci. 2015;17(2):127\u201340.","journal-title":"Dialogues Clin Neurosci."},{"issue":"1","key":"282_CR143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1744-859X-4-1","volume":"4","author":"M Sala","year":"2005","unstructured":"Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4(1):1.","journal-title":"Ann Gen Psychiatry"},{"issue":"5","key":"282_CR144","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00023210-200923050-00006","volume":"23","author":"KF Croom","year":"2009","unstructured":"Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427\u201352.","journal-title":"CNS Drugs"},{"issue":"11","key":"282_CR145","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.biopsych.2005.12.007","volume":"59","author":"M Poyurovsky","year":"2006","unstructured":"Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry. 2006;59(11):1071\u20137.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"282_CR146","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40263-014-0192-0","volume":"28","author":"JE Frampton","year":"2014","unstructured":"Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014;28(9):835\u201354.","journal-title":"CNS Drugs"},{"issue":"4","key":"282_CR147","doi-asserted-by":"crossref","first-page":"453","DOI":"10.31887\/DCNS.2011.13.4\/kholzschneider","volume":"13","author":"K Holzschneider","year":"2011","unstructured":"Holzschneider K, Mulert C. Neuroimaging in anxiety disorders. Dialogues Clin Neurosci. 2011;13(4):453\u201361.","journal-title":"Dialogues Clin Neurosci."},{"issue":"8","key":"282_CR148","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5414\/CP202118","volume":"52","author":"G Papazisis","year":"2014","unstructured":"Papazisis G, Tzachanis D. Pregabalin\u2019s abuse potential: a mini review focusing on the pharmacological profile. Int J Clin Pharmacol Ther. 2014;52(8):709\u201316.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"282_CR149","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","volume":"28","author":"F Schifano","year":"2014","unstructured":"Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28(6):491\u20136.","journal-title":"CNS Drugs"},{"issue":"1","key":"282_CR150","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/JCP.0b013e31823f6540","volume":"32","author":"S Englisch","year":"2012","unstructured":"Englisch S, Alm B, Meyer-Lindenberg A, Zink M. Pregabalin-associated increase of clozapine serum levels. J Clin Psychopharmacol. 2012;32(1):127.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"282_CR151","first-page":"1259","volume":"16","author":"T Kishi","year":"2013","unstructured":"Kishi T, Meltzer HY, Iwata N. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol. 2013;16(6):1259\u201366.","journal-title":"Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol"},{"issue":"9","key":"282_CR152","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.euroneuro.2013.03.001","volume":"23","author":"M Dold","year":"2013","unstructured":"Dold M, Li C, Gillies D, Leucht S. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2013;23(9):1023\u201333.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"issue":"11","key":"282_CR153","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4088\/JCP.11m07164","volume":"73","author":"BAA Scheltema","year":"2012","unstructured":"Scheltema BAA, Swets M, Machielsen M, Korver N. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients. J Clin Psychiatry. 2012;73(11):1395\u2013402.","journal-title":"J Clin Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0282-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0282-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0282-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T18:03:20Z","timestamp":1653329000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0282-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":153,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["282"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0282-7","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}